View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
July 19, 2021updated 11 Jul 2022 3:10pm

Central nervous system resumed trials showed biggest increase since beginning of 2021

Of all therapy areas, the central nervous system has seen the biggest increase in resumed clinical trials since the start of the year.

By GlobalData Healthcare

As the Covid-19 pandemic has begun to ease, with vaccines being manufactured and distributed, more clinical trials are continuing to resume. Data captured from GlobalData’s Pharma Intelligence Centre on 28 June shows that more than 1,000 trials have resumed, with resumed trials showing a widespread distribution over therapy areas.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Out of the resumed trials, 30.5% are currently in the oncology therapy area, followed by the central nervous system at 19.6% and infectious diseases at 8.3%. The figure below shows the top ten therapy areas for resumed trials. Since the beginning of the year, oncology has seen a 10.3% increase. The central nervous system saw the biggest increase in the number of resumed clinical trials since early in the year at 29.6%, while dermatology had the smallest increase at 5.6%.

These numbers suggest a positive outlook for resumed clinical trials, although this could be slowed by new variant strains such as Delta and warnings of new waves of the original Covid-19 strain.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena